1/12
08:00 am
cvkd
Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibito
Medium
Report
Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibito
12/30
07:07 pm
cvkd
Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System [Yahoo! Finance]
Low
Report
Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System [Yahoo! Finance]
12/29
08:12 am
cvkd
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On [Yahoo! Finance]
Medium
Report
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On [Yahoo! Finance]
12/17
09:00 am
cvkd
Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026
Medium
Report
Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026
12/11
08:27 am
cvkd
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT) [Yahoo! Finance]
Medium
Report
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT) [Yahoo! Finance]
12/11
08:05 am
cvkd
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
Medium
Report
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
12/1
09:00 am
cvkd
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
Low
Report
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
11/19
08:00 am
cvkd
Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award
Medium
Report
Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award
11/17
03:25 pm
cvkd
Why the underdog mindset could be your business superpower [Yahoo! Finance]
Low
Report
Why the underdog mindset could be your business superpower [Yahoo! Finance]
11/10
03:55 pm
cvkd
Cadrenal Therapeutics GAAP EPS of -$1.31 beats by $0.18 [Seeking Alpha]
Low
Report
Cadrenal Therapeutics GAAP EPS of -$1.31 beats by $0.18 [Seeking Alpha]
11/10
09:00 am
cvkd
Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Low
Report
Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/8
12:52 pm
cvkd
Cadrenal Therapeutics, Inc. [Yahoo! Finance]
Low
Report
Cadrenal Therapeutics, Inc. [Yahoo! Finance]